Federal contract award
HT942524P0161
MANUFACTURING OF ARMY LIPOSOME FORMULATION FOR CLINICAL TRAILS PHASE 2 AND 3 FOR WALTER REED ARMY INSTITUTE OF RESEARCH.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 325411 — Medicinal and Botanical Manufacturing |
| PSC | Q517 — Pharmacy Services |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | $0 |
| Potential contract value / ceiling | $0 |
| Start date | Sep 20, 2024 |
| Current end date | Mar 22, 2026 |
| Potential end date | Mar 22, 2026 |
| Latest award activity | Aug 12, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 12, 2025 | P00002 | $-1.2M | MANUFACTURING OF ARMY LIPOSOME FORMULATION CONTAINING QS-21 |
| Oct 7, 2024 | P00001 | $0 | RESEARCH DEVELOPMENT FOR DRUG MANUFACTURING OF PHASE 2 AND 3 ARMY LIPOSOME FORMULATION CONTAINING QS-21 UNDER CURRENT GOOD MANUFACTURING PRACTICES |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.